TY - JOUR
T1 - Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia
T2 - A Pediatric Oncology Group study
AU - Sadowitz, P. D.
AU - Dubowy, R.
AU - Souid, A.
AU - Pollock, B. H.
AU - Weinstein, H.
AU - Parmley, R. T.
AU - Bowman, W. P.
AU - Land, V.
AU - Vats, T.
AU - Pratt, C.
AU - Buchanan, G. R.
PY - 1994/9
Y1 - 1994/9
N2 - Purpose: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia. Patients and Methods: From January 1989 to February 1992, 20 patients received 28 courses of treatment. Each course of treatment consisted of a 1- hour intravenous (IV) infusion of VP-16 100 mg/m2/d for 5 days, followed by a 23-hour IV infusion of carboplatin each day. The initial, total 5-day dose of carboplatin (1,000 mg/m2) was escalated by 250- to 375-mg increments to a final, total dose of 1,875 mg/m2 over 5 days. Results: Significant marrow suppression was observed in all patients, with prolonged marrow aplasia at the 1,875-mg/m2 dose level. Grade III diarrhea occurred in three patients; 10 patients experienced life-threatening infection and three had severe thrombocytopenic bleeding. Major marrow responses (two complete remissions and two partial remissions) occurred in four patients (20%). Conclusion: In view of the apparent antileukemic efficacy and minimal extramedullary toxicity, carboplatin deserves further study in a phase II trial.
AB - Purpose: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia. Patients and Methods: From January 1989 to February 1992, 20 patients received 28 courses of treatment. Each course of treatment consisted of a 1- hour intravenous (IV) infusion of VP-16 100 mg/m2/d for 5 days, followed by a 23-hour IV infusion of carboplatin each day. The initial, total 5-day dose of carboplatin (1,000 mg/m2) was escalated by 250- to 375-mg increments to a final, total dose of 1,875 mg/m2 over 5 days. Results: Significant marrow suppression was observed in all patients, with prolonged marrow aplasia at the 1,875-mg/m2 dose level. Grade III diarrhea occurred in three patients; 10 patients experienced life-threatening infection and three had severe thrombocytopenic bleeding. Major marrow responses (two complete remissions and two partial remissions) occurred in four patients (20%). Conclusion: In view of the apparent antileukemic efficacy and minimal extramedullary toxicity, carboplatin deserves further study in a phase II trial.
UR - http://www.scopus.com/inward/record.url?scp=0028099999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028099999&partnerID=8YFLogxK
U2 - 10.1200/JCO.1994.12.9.1969
DO - 10.1200/JCO.1994.12.9.1969
M3 - Article
C2 - 8083718
AN - SCOPUS:0028099999
SN - 0732-183X
VL - 12
SP - 1969
EP - 1973
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -